Breaking News

Karyopharm Awarded MS Research Grant

By Kristin Brooks | January 8, 2014

To evaluate the potential of SINE compounds in inflammatory disease

Karyopharm Therapeutics Inc. has been awarded a grant from the National Multiple Sclerosis (MS) Society through its affiliate, Fast Forward, to support research on the potential of SINE compounds in inflammatory disease, including MS.
 
SINE compounds inhibit Exportin-1 (XPO1 or CRM1), which mediates the export of mammalian cargo proteins. In MS, toxic factors accumulate in the brain and spinal cord that may attack or destroy the myelin coating on a neuron's axon leading to neurodegenerative symptoms. Preclinical data suggest that SINE compounds may reduce inflammation and protect against these toxic factors in neurons.
 
"We are very excited about our continuing collaboration with the National MS Society, and with Mount Sinai with Dr. Patrizia Casaccia, who has dedicated herself to advancing research in MS and other important diseases," said Karyopharm founder, chief scientific officer, and president, Sharon Shacham, Ph.D., M.B.A. "We believe SINE compounds may offer significant therapeutic benefits in a range of indications and look forward to exploring the potential application of SINE compounds in inflammatory diseases, including MS."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers